{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-061361","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.098870+00:00","generated_at":"2026-05-24T06:51:19.026885+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Surrozen secures $175M PIPE for ophthalmology Wnt mimetics, drops liver program","bullets":["Oversubscribed $175M private placement (two tranches: $70M initial, $105M contingent on FDA clearance) led by Venrock Healthcare Capital Partners.","Prioritizes ophthalmology pipeline: lead candidates SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6) for retinopathies.","Discontinues SZN-043 in severe alcohol-associated hepatitis due to insufficient clinical benefit signal relative to development path.","Tim Kutzkey, Ph.D. joins Board of Directors; Series A/B warrant exercise prices reduced, Series C/D warrants cancelled.","Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-061361","json":"https://secwatch.observer/filing/0001193125-25-061361.json","markdown":"https://secwatch.observer/filing/0001193125-25-061361.md","text":"https://secwatch.observer/filing/0001193125-25-061361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/0001193125-25-061361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312525061361/d923940d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:51:19.026885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}